ӳ��ý

B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV.

Scheid JF, Barnes CO, Eraslan B, et al. B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. Cell. 2021;184(12):3205-3221.e24. doi:10.1016/j.cell.2021.04.032

A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite.

Kisalu NK, Idris AH, Weidle C, et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat Med. 2018;24(4):408-416. doi:10.1038/nm.4512

Versatile and on-demand biologics co-production in yeast.

Cao J, Perez-Pinera P, Lowenhaupt K, et al. Versatile and on-demand biologics co-production in yeast. Nat Commun. 2018;9(1):77. doi:10.1038/s41467-017-02587-w

Resistance to checkpoint blockade therapy through inactivation of antigen presentation.

Sade-Feldman M, Jiao YJ, Chen JH, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017;8(1):1136. doi:10.1038/s41467-017-01062-w

A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.

Khetarpal SA, Zeng X, Millar JS, et al. A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels. Nat Med. 2017;23(9):1086-1094. doi:10.1038/nm.4390

Dissecting FcγR Regulation through a Multivalent Binding Model.

Robinett RA, Guan N, Lux A, Biburger M, Nimmerjahn F, Meyer AS. Dissecting FcγR Regulation through a Multivalent Binding Model. Cell Syst. 2018;7(1):41-48.e5. doi:10.1016/j.cels.2018.05.018

Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade.

Shukla SA, Bachireddy P, Schilling B, et al. Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell. 2018;173(3):624-633.e8. doi:10.1016/j.cell.2018.03.026

RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study.

Tripp CS, Cuff C, Campbell AL, et al. RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study. Adv Ther. 2017;34(6):1364-1381. doi:10.1007/s12325-017-0525-8

Identification and structural analysis of residues in the V1 region of CD4 involved in interaction with human immunodeficiency virus envelope glycoprotein gp120 and class II major histocompatibility complex molecules.

Bowman MR, MacFerrin KD, Schreiber SL, Burakoff SJ. Identification and structural analysis of residues in the V1 region of CD4 involved in interaction with human immunodeficiency virus envelope glycoprotein gp120 and class II major histocompatibility complex molecules. Proc Natl Acad Sci U S A. 1990;87(22):9052-6.

Association of a 59-kilodalton immunophilin with the glucocorticoid receptor complex.

Tai PK, Albers MW, Chang H, Faber LE, Schreiber SL. Association of a 59-kilodalton immunophilin with the glucocorticoid receptor complex. Science. 1992;256(5061):1315-8.